Loading...
XNAS
TNDM
Market cap1.16bUSD
Jul 22, Last price  
16.91USD
1D
-3.92%
1Q
-18.23%
Jan 2017
-21.35%
IPO
-91.22%
Name

Tandem Diabetes Care Inc

Chart & performance

D1W1MN
XNAS:TNDM chart
P/E
P/S
1.14
EPS
Div yield, %
Shrs. gr., 5y
1.98%
Rev. gr., 5y
15.26%
Revenues
1.01b
+7.93%
02,474,69829,006,63849,722,00072,850,00084,248,000107,601,000183,866,000362,305,000498,830,000702,799,000801,217,000747,718,000940,203,0001,014,736,000
Net income
-205m
L+113.18%
-25,509,824-33,015,085-63,138,849-79,524,000-72,418,000-83,447,000-73,033,000-122,611,000-24,753,000-34,382,00015,566,000-94,594,000-222,611,000-96,025,000-204,710,000
CFO
-10m
L
-21,546,786-33,471,166-47,756,651-61,378,000-58,764,000-61,173,000-66,136,000-8,319,00041,906,00024,669,000111,359,00050,464,000-31,810,00024,225,000-9,721,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
IPO date
Nov 13, 2013
Employees
2,600
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT